MAPI-PHARMA

Mapi Pharma is a clinical stage pharmaceutical company, developing proprietary pharmaceuticals, including life cycle management (LCM) products such as Depot long acting injections, complex active pharmaceutical ingredients (APIs) and formulations. The company's lead product is Glatiramer Acetate (GA, Copaxone®) Depot, a once-monthly IM injection of 40mg GA for the treatment of multiple sclerosis (a $20 billion market). Mapi is engaged in the development of Pregabalin ER for the treatment of neuropathic pain and epilepsy, Paliperidone Palmitate and Buspirone ER for the treatment of schizophrenia and other long acting Depot injectable treatments. Mapi Pharma Ltd. was founded in 2008 and is located in Ness Ziona, Israel and has GMP approved API and FDF facilities... Our lead product candidate is Glatiramer Acetate Depot, a once-monthly injection for the treatment of patients with multiple sclerosis, in contrast to the daily 20 mg and the thrice-weekly 40 mg dosage of Copaxone®, Teva..

Also known as: Mapi-Pharma Ltd.

Primary location: Ness Ziona Israel